{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Melanoma", "query": { "condition": "Refractory Melanoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 143, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Melanoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T09:58:48.204Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05130177", "title": "Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diwakar Davar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-16", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130177" }, { "nct_id": "NCT04993677", "title": "A Study of SEA-CD40 Given With Other Drugs in Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Carcinoma, Non-Small- Cell Lung" ], "interventions": [ { "name": "SEA-CD40", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-10-06", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 23, "location_summary": "Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04993677" }, { "nct_id": "NCT03595683", "title": "Pembrolizumab and EDP1503 in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "EDP1503", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-10-02", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595683" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2022-11-17", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" }, { "nct_id": "NCT03501368", "title": "Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Unresectable Melanoma", "Advanced Melanoma" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501368" }, { "nct_id": "NCT01391143", "title": "Safety Study of MGA271 in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Head and Neck Cancer", "Bladder Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2011-07", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391143" }, { "nct_id": "NCT06880549", "title": "A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "mRNA-4106", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "mRNA-4200", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-03-25", "completion_date": "2027-08-03", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • San Antonio, Texas • West Valley City, Utah", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06880549" }, { "nct_id": "NCT00689065", "title": "Safety Study of CALAA-01 to Treat Solid Tumor Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "CALAA-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calando Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2008-05", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689065" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT03991741", "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Locally Advanced Refractory/Recurrent Melanoma", "Metastatic Head and Neck Cancer", "Locally Advanced Refractory/Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" }, { "name": "High-Dose Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gregory Daniels", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-10-07", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-06-25T09:58:48.204Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03991741" } ] }